Peptide Vaccines for Cancer

Peptide-based cancer vaccines stimulate tumor-specific immune responses by presenting defined antigenic epitopes to T cells, offering a personalized approach to cancer immunotherapy. Despite initial clinical disappointment, advances in neoantigen prediction, adjuvant delivery, and combination strategies with checkpoint inhibitors have renewed enthusiasm for peptide vaccination.

Tumor-Associated Antigens

Classical tumor-associated antigens (TAAs) include overexpressed self-proteins such as HER2/neu, MUC1, CEA, and survivin. These antigens provide shared targets across patient populations but face central tolerance mechanisms that limit T cell responsiveness. Multi-peptide vaccines targeting multiple TAAs simultaneously achieve objective responses in 10-15% of patients with advanced solid tumors. Peptide vaccines targeting cancer-testis antigens (NY-ESO-1, MAGE-A3) exploit tissue-restricted expression patterns to circumvent tolerance, with NY-ESO-1 vaccines generating antibody and T cell responses in over 50% of vaccinated patients.

Neoantigen Vaccines

Tumor-specific neoantigens arising from somatic mutations provide truly foreign targets不受 central tolerance constraints. Whole-exome sequencing combined with HLA-binding prediction algorithms identifies patient-specific neoantigen candidates with 70-90% positive predictive value for immunogenicity. Neoantigen peptide vaccines administered with appropriate adjuvants generate neoantigen-specific T cell responses in 60-80% of vaccinated patients, with objective clinical responses correlating with high neoantigen burden and pre-existing T cell infiltration.

Combination with Checkpoint Inhibitors

Rational combination of peptide vaccines with immune checkpoint inhibitors addresses the immunosuppressive tumor microenvironment. Vaccination primes tumor-specific T cells while anti-PD-1/PD-L1 therapy reinvigorates exhausted T cell populations. Phase II trials demonstrate that neoantigen vaccination plus pembrolizumab achieves objective response rates of 25-35% in treatment-refractory melanoma and non-small cell lung cancer, significantly exceeding either modality alone. Ongoing trials explore triple combinations incorporating CTLA-4 blockade and adoptive T cell transfer.

Delivery and Adjuvant Strategies

Peptide vaccine efficacy depends critically on adjuvant selection and delivery platform. Toll-like receptor agonists (CpG-ODN, poly(I:C), imiquimod) provide innate immune activation essential for T cell priming. Liposomal and nanoparticle delivery systems enhance lymph node trafficking and antigen presentation, with self-assembling peptide nanoparticles achieving 5-10 fold improvements in immunogenicity compared to adjuvant-peptide mixtures.